IBAB Ion Beam Applications SA

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)

Louvain-la-Neuve, Belgium, February 25, 2026 06:00 PM

Summary of the notification

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on February 13, 2026.

In its notification, Premier Miton Group plc indicated that following an acquisition or disposal of securities or voting rights, the 4% threshold has been crossed downwards by Premier Fund Managers Ltd, a controlled undertaking of Premier Miton Group plc on February 10, 2026.

Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights, and downward crossing of the threshold
  • Notification by: A parent company or controlling person
  • Persons subject to the notification requirement:



NameAddress (for legal entities)
Premier Fund Managers Ltd (100% owned by Premier Miton Group plc)Eastgate Court, High Street, Guildford, GU1 3DE, United Kingdom
Premier Miton Group plcEastgate Court, High Street, Guildford, GU1 3DE, United Kingdom
  • Date on which the threshold is crossed: 10-02-2026
  • Threshold crossed (in %): 4%
  • Denominator: 40,514,366
  • Notified details: (extract of the received notification form)



A) Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked

to the securities
Linked to securitiesNot linked to the securities
Premier Miton Group plc00000
Premier Fund Managers Ltd (100% owned by Premier Miton Group plc)01,609,96003.97%0
Subtotal01,609,96003.97%0
TOTAL1,609,96003.97%0.00%



B) Equivalent financial instrumentsAfter the transaction
Holders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
       
TOTAL00.00% 



 



TOTAL (A & B)
 



# of voting rights
 



% of voting rights
 1,609,9603.97%
  • Full chain of controlled undertakings through which the holding is effectively held

Premier Fund Managers Ltd



About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

For further information, please contact:

Elena De Landy

Paralegal: Corporate Affairs and Insurance 

Attachment



EN
25/02/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

IBA: IBA to supply 4 Cyclone KIUBE cyclotrons to Telix Pharmaceuticals in US. Lotus Bakeries: Biscoff spread shortages in DACH countries. Unilever plc: Morris dancing. Zabka: Small beat in 4Q25, guidance reiterated for FY26

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Livio Luyten
  • Wim Hoste
  • Wim Lewi
 PRESS RELEASE

Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in...

Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S. Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced it has signed a contract with Telix Pharmaceuticals Limited (Telix; ASX: TLX, NASDAQ: TLX), a precision oncology company, for the initial order of four Cyclone® KIUBE cyclotrons at standard IBA conditions1. The systems will be installed at select RLS Radiopharmacies (RLS) sites in...

 PRESS RELEASE

Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de pr...

Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis Louvain‑la‑Neuve, Belgique, le 20 mars 2026 — IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de production de radiopharmaceutiques, annonce la signature d’un contrat avec Telix Pharmaceuticals Limited (Telix ; ASX : TLX, NASDAQ : TLX), entreprise d’oncologie de précision, pour une première commande de quatre cyclotrons Cyclone® KIUBE aux conditions standards d’IBA1. Les systèmes seront installés...

 PRESS RELEASE

IBA Notice of Full Year 2025 Results and Conference Call

IBA Notice of Full Year 2025 Results and Conference Call FY25 results webcast to take place on Friday, 27 March 2026 at 3pm CET Louvain-la-Neuve, Belgium, 13 March 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2025 on Friday, 27 March 2026 at 7am CET. Conference Call Information IBA’s management team will host team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session. The conference...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch